MedTrace Logo

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

NCT01721707 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-12-11

No results posted yet for this study

Summary

This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension.

The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL / brinzolamide 10mg/ml eye drops compared to Latanoprost 50μg/mL eye drops in reducing IOP

Conditions

Interventions

DRUG

Latanoprost+Brinzolamide combination

1 drop in each eye, 1x/day, at 9PM

DRUG

Latanoprost

1 drop in each eye, 1x/day, at 9PM

Sponsors & Collaborators

  • Adapt Produtos Oftalmológicos Ltda.

    lead INDUSTRY

Principal Investigators

  • Rubens Belfort Jr, MD · Federal University of São Paulo / Hospital São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-03-31
Completion
2013-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01721707 on ClinicalTrials.gov